Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3684612 | 0.93 | L3MBTL1 (0.43) | CMA1L3MBTL1PTGS2KMT2A | |
| SCHEMBL3684609 | 0.93 | L3MBTL1 (0.43) | CMA1L3MBTL1PTGS2KMT2A | |
| SCHEMBL3686010 | 0.93 | L3MBTL1 (0.43) | CMA1L3MBTL1PTGS2KMT2A | |
| SCHEMBL3681840 | 0.91 | CMA1 (0.47) | CMA1FFAR1GPR84KMT2A | |
| SCHEMBL3681842 | 0.91 | CMA1 (0.47) | CMA1FFAR1GPR84KMT2A | |
| SCHEMBL3699285 | 0.91 | CMA1 (0.47) | CMA1FFAR1GPR84KMT2A | |
| SCHEMBL3689846 | 0.90 | CMA1 (0.36) | CMA1L3MBTL1PTGS2FFAR1GPR84 | |
| SCHEMBL3689843 | 0.90 | CMA1 (0.36) | CMA1L3MBTL1PTGS2FFAR1GPR84 | |
| SCHEMBL3690079 | 0.90 | CMA1 (0.39) | CMA1FFAR1GPR84KMT2AGPR139 | |
| SCHEMBL3690074 | 0.90 | CMA1 (0.39) | CMA1FFAR1GPR84KMT2AGPR139 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8377949-B2 | Quinazolinedione chymase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-19 | — | — | US | disclosed |
| EP-2188277-B1 | QUINAZOLINEDIONE CHYMASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2012-11-21 | — | — | EP | disclosed |
| US-20120122863-A1 | Quinazolinedione Chymase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-17 | — | — | US | disclosed |
| EP-2188277-A1 | QUINAZOLINEDIONE CHYMASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2010-05-26 | — | — | EP | disclosed |
| WO-2009023655-A1 | QUINAZOLINEDIONE CHYMASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122863-A1 | Quinazolinedione Chymase Inhibitors | CMA1, CTSC, TPSG1 | CMA1 1/4885L3MBTL1 4042/4885PTGS2 1440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.